AI-generated analysis. Always verify with the original filing.
Moleculin Biotech, Inc. reported full year 2025 financial results including R&D expenses of $15.9 million (down from $17.7 million in 2024), G&A expenses of $9.2 million, net loss of $33.6 million, and cash of $8.9 million as of December 31, 2025. The company highlighted a preliminary blinded CRc rate of 40% in the first 30 patients of the MIRACLE trial for R/R AML, with 45-patient interim unblinding on track for mid-2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 19, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial result
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 19, 2026 104 Cover page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Research and development expense | $15.90 | GAAP |
| General and administrative expense | $9.20 | GAAP |
| Loss from operations | $-25.10 | GAAP |
| Net loss | $-33.60 | GAAP |
| Net loss per common share - basic and diluted | $-28.42 | GAAP |